TMOD

Serial Number 90370290
734

Registration Progress

Application Filed
Dec 9, 2020
Under Examination
Nov 22, 2022
Approved for Publication
Sep 27, 2022
Published for Opposition
Sep 27, 2022
Registered

Trademark Image

TMOD

Basic Information

Serial Number
90370290
Filing Date
December 9, 2020
Published for Opposition
September 27, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
734
Status Date
Aug 11, 2025
Application
Pending
Classes
005 040 042

Rights Holder

A2 Biotherapeutics, Inc.

03
Address
30301 Agoura Road, Suite 210
Agoura Hills, CA 91301

Ownership History

A2 Biotherapeutics, Inc.

Original Applicant
03
Agoura Hills, CA

A2 Biotherapeutics, Inc.

Owner at Publication
03
Agoura Hills, CA

Legal Representation

Attorney
Joi A. White

USPTO Deadlines

All Deadlines Cleared

All 1 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

48 events
Date Code Type Description Documents
Nov 24, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Aug 12, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 11, 2025 EX5G S SOU EXTENSION 5 GRANTED Loading...
May 14, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
May 14, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
May 14, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 22, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 22, 2024 EX4G S SOU EXTENSION 4 GRANTED Loading...
Oct 22, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Oct 22, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 15, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 14, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
May 14, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
May 14, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 21, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 17, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Nov 17, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Nov 17, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 11, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 9, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
May 9, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
May 9, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 22, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 27, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 27, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 7, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 18, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 18, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 17, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 17, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 13, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jul 13, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jul 13, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
May 22, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
May 22, 2022 GNRT O NON-FINAL ACTION E-MAILED Loading...
May 22, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 6, 2022 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN Loading...
Mar 8, 2022 PBCR Z WITHDRAWN FROM PUB - OG REVIEW QUERY Loading...
Feb 19, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 18, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 17, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 17, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Aug 18, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 18, 2021 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 18, 2021 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 28, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 16, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 12, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical products for the treatment and prevention of cancer and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; biological technology platforms consisting of modified cells, cell receptors, proteins and protein complexes for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; cell platform consisting of modified cells, cell receptors, proteins and protein complexes for autologous and allogeneic cell manufacturing; therapeutics and cell therapies in the nature of proteins and protein complexes targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes
Class 040
custom manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapeies for the treatment and prevention of cancer, inflammation and inflammatory diseases using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing of biological cells, proteins, and antibodies for others for treatment and prevention of cancer, inflammation and inflammatory disease
Class 042
Identification and development of, therapeutic targets, namely, proteins and protein complexes, for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of therapeutics and cell therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of cancer, inflammation, and inflammatory diseases; scientific research and development services; providing scientific information in the fields of treatment and prevention of cancer, inflammation and inflammatory diseases; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services; engineering of biological cells, cellular targets, proteins, and antibodies for others

Classification

International Classes
005 040 042